EMEA-003066-PIP01-21

Table of contents

Key facts

Active substance
  • Bordetella pertussis antigen: Filamentous Haemagglutinin
  • Bordetella pertussis antigen: Pertactin
  • Bordetella pertussis antigen: Pertussis toxoid
  • Inactivated poliovirus: type 1 (Mahoney strain)
  • Inactivated poliovirus: type 2 (MEF-1 strain)
  • Inactivated poliovirus: type 3 (Saukett strain)
  • tetanus toxoid
Therapeutic area
  • Infectious diseases
  • Vaccines
Decision number
P/0489/2021
PIP number
EMEA-003066-PIP01-21
Pharmaceutical form(s)
Solution for injection in pre-filled syringe
Condition(s) / indication(s)
Prevention of infectious diseases caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, Poliovirus types 1, 2 and 3
Route(s) of administration
Intramuscular use
Contact for public enquiries
Vakzine Projekt Management GmbH

Email: info@vakzine-manager.de
Tel. +49 15111699080
Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating